RhoGAM may help protect your patients from Rh-sensitization. Rh-sensitization of the mother during pregnancy can lead to hemolytic disease of the fetus and newborn (HDFN) in future pregnancies.
RhoGAM is typically administered twice to expectant mothers – once during pregnancy and once after delivery. RhoGAM is an intramuscular injection given by a healthcare professional to the mother.
- If the mother’s blood type is Rh-negative, the 1st injection of RhoGAM is delivered between 26-28 weeks of pregnancy
- If the baby is found to be Rh-positive at birth, administer within 72 hours of delivery
- If the baby is determined to be Rh-negative at birth, an additional dose is not needed
Additional doses of RhoGAM are indicated when the patient has been exposed to more than 15 mL of Rh-positive red blood cells. This may be determined by use of qualitative or quantitative tests for fetal-maternal hemorrhage.
For complete dosing & administration information, click here for the RhoGAM Full Prescribing Information.
References: 1. RhoGAM Ultra-Filtered PLUS [prescribing Information]. Fort Lee, NJ. Kedrion Biopharma Inc. 2019. 2. The plasma proteins market in the United States, 2017. The Marketing Research Bureau. Orange, CT: 2018.